MAINZ BIOMED B.V. MYNZ 深 滬
等待開盤 09-22 09:30:00 美东时间
1.61
-0.040
-2.42%
華盛通- 最 高1.69
- 今 開1.66
- 成交量 3.51万股
- 最 低 1.57
- 昨 收 1.65
- 總市值 1094.82万
- 52周最高 16.04
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 1.30
- 委 比 99.25%
- 總股本 680.01万
- 歷史最高 1200.00
- 量 比 0.65
- 振 幅 7.27%
- 歷史最低 1.30
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mainz Biomed's ColoAlert Receives MHRA Approval For Colorectal Cancer Screening In The UK
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official
09-02 20:11
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
Mainz Biomed's ColoAlert®, a non-invasive DNA-based colorectal cancer screening test, has been officially registered with the UK's MHRA and authorized for marketing. This milestone, achieved through a partnership with EDX Medical Group, aims to increase accessibility and participation in CRC screening, addressing the UK's fourth most common cancer. ColoAlert detects DNA biomarkers in stool samples, complementing existing screening programs and of...
09-02 12:01
Mainz Biomed's ColoAlert Receives Swissmedic Approval, Paving Way For Swiss Launch Of Non-Invasive Colorectal Cancer Test
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal
08-13 20:18
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
Mainz Biomed's ColoAlert®, a non-invasive colorectal cancer (CRC) screening test, has received regulatory approval from Swissmedic, allowing its distribution in Switzerland. Targeting individuals aged 50-74, a group of around 2.8 million people, ColoAlert® aims to address the low participation rate in CRC screening programs (below 50%) and support national health goals. The approval follows a partnership with a local Swiss laboratory, enabling br...
08-13 12:01
Mainz Biomed Prices $3.0M Follow-On Offering of Over 2.2M Units Including Ordinary Shares and Series A Warrants
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of
08-04 22:24
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed announces a $3.0 million follow-on offering of 2,222,222 units at $1.35 per unit, each consisting of one ordinary share or pre-funded warrant and one Series A warrant exercisable at $1.35 per share. The offering, managed by Maxim Group LLC, is set to close on August 5, 2025, pending customary conditions. The securities are registered under SEC's Form F-1 (File No. 333-289095). Investors can obtain the prospectus from Maxim Group.
08-04 14:22
Mainz Biomed files to sell 1.47M ordinary units
Mainz Biomed (NASDAQ:MYNZ) filed a prospectus for the offer and sale of up to 1.47M ordinary units. This preliminary prospectus is not an offer to sell. Filing. More on Mainz Biomed B.V. Mainz Biome...
07-31 04:58
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
Mainz Biomed collaborates with CARE to expand ColoAlert® colorectal cancer screening in Germany, enhancing early detection rates. CARE currently works with 19 health insurance companies, supporting Mainz Biomed's market growth.
07-23 12:01
Mainz Biomed Reviews H1 2025 Accomplishments; Plans To Complete eAArly DETECT 2 Feasibility Study In H2 2025.
Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over
07-15 20:09
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Mainz Biomed has made significant strides in advancing its colorectal and pancreatic cancer screening technologies. The company initiated the eAArly DETECT 2 feasibility study for its next-gen CRC test, launched ColoAlert® in Switzerland, and entered collaborations to expand its product portfolio. Additionally, it secured a license for novel mRNA biomarkers for pancreatic cancer detection, with high sensitivity and specificity, and received publi...
07-15 12:01
